BACKGROUND: Tolerance to composite tissue allografts might allow the widespread clinical use of reconstructive allotransplantation if protocols to achieve this could be rendered sufficiently nontoxic. The authors investigated whether tolerance could be generated in miniature swine to composite tissue allografts across a major histocompatibility (MHC) barrier. A clinically relevant tolerance protocol involving hematopoietic cell transplantation without the need for irradiation or myelosuppressive drugs was tested. METHODS: Seven recipient animals were transiently T-cell depleted and a short course of cyclosporine was initiated. Twenty-four hours later, a donor hematopoietic cell transplant consisting of cytokine-mobilized peripheral blood mononuclear cells or bone marrow cells and a heterotopic limb transplant were performed. In vitro anti-donor responsiveness was assessed by mixed-lymphocyte reaction and cell-mediated lympholysis assays. Acceptance of the limb allografts was determined by gross and histologic appearance. Chimerism in the peripheral blood and lymphohematopoietic organs was assessed by flow cytometry. RESULTS: All seven experimental animals accepted the musculoskeletal elements but rejected the skin of the allografts. All but one of the animals displayed donor-specific unresponsiveness in vitro. The animals that received cytokine mobilized-peripheral blood mononuclear cells showed chimerism but had clinical evidence of graft-versus-host disease (GVHD). None of the animals that received bone marrow cells showed stable chimerism and none developed GVHD. CONCLUSIONS: This protocol can achieve tolerance to the musculoskeletal elements of composite tissue allografts across an MHC barrier in miniature swine. Stable chimerism does not appear to be necessary for tolerance and may not be desirable because of the risk of GVHD.
BACKGROUND: Tolerance to composite tissue allografts might allow the widespread clinical use of reconstructive allotransplantation if protocols to achieve this could be rendered sufficiently nontoxic. The authors investigated whether tolerance could be generated in miniature swine to composite tissue allografts across a major histocompatibility (MHC) barrier. A clinically relevant tolerance protocol involving hematopoietic cell transplantation without the need for irradiation or myelosuppressive drugs was tested. METHODS: Seven recipient animals were transiently T-cell depleted and a short course of cyclosporine was initiated. Twenty-four hours later, a donor hematopoietic cell transplant consisting of cytokine-mobilized peripheral blood mononuclear cells or bone marrow cells and a heterotopic limb transplant were performed. In vitro anti-donor responsiveness was assessed by mixed-lymphocyte reaction and cell-mediated lympholysis assays. Acceptance of the limb allografts was determined by gross and histologic appearance. Chimerism in the peripheral blood and lymphohematopoietic organs was assessed by flow cytometry. RESULTS: All seven experimental animals accepted the musculoskeletal elements but rejected the skin of the allografts. All but one of the animals displayed donor-specific unresponsiveness in vitro. The animals that received cytokine mobilized-peripheral blood mononuclear cells showed chimerism but had clinical evidence of graft-versus-host disease (GVHD). None of the animals that received bone marrow cells showed stable chimerism and none developed GVHD. CONCLUSIONS: This protocol can achieve tolerance to the musculoskeletal elements of composite tissue allografts across an MHC barrier in miniature swine. Stable chimerism does not appear to be necessary for tolerance and may not be desirable because of the risk of GVHD.
Authors: Zuhaib Ibrahim; Damon S Cooney; Jaimie T Shores; Justin M Sacks; Eric G Wimmers; Steven C Bonawitz; Chad Gordon; Dawn Ruben; Stefan Schneeberger; W P Andrew Lee; Gerald Brandacher Journal: J Vis Exp Date: 2013-10-14 Impact factor: 1.355
Authors: D A Leonard; J M Kurtz; C Mallard; A Albritton; R Duran-Struuck; E A Farkash; R Crepeau; A Matar; B M Horner; M A Randolph; D H Sachs; C A Huang; C L Cetrulo Journal: Am J Transplant Date: 2014-01-09 Impact factor: 8.086
Authors: David W Mathes; Billanna Hwang; Scott S Graves; James Edwards; Jeff Chang; Barry E Storer; Tiffany Butts-Miwongtum; George E Sale; Richard A Nash; Rainer Storb Journal: Transplantation Date: 2011-12-27 Impact factor: 4.939
Authors: Jeff Chang; Scott S Graves; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb; David Woodbridge Mathes Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: Stefan Schneeberger; Vijay S Gorantla; Gerald Brandacher; Adriana Zeevi; Anthony J Demetris; John G Lunz; Diana M Metes; Albert D Donnenberg; Jaimie T Shores; Andrea F Dimartini; Joseph E Kiss; Joseph E Imbriglia; Kodi Azari; Robert J Goitz; Ernest K Manders; Vu T Nguyen; Damon S Cooney; Galen S Wachtman; Jonathan D Keith; Derek R Fletcher; Camila Macedo; Raymond Planinsic; Joseph E Losee; Ron Shapiro; Thomas E Starzl; W P Andrew Lee Journal: Ann Surg Date: 2013-02 Impact factor: 12.969
Authors: R A Nash; M Yunosov; K Abrams; B Hwang; C Castilla-Llorente; P Chen; A S Farivar; G E Georges; R C Hackman; W J E Lamm; M Lesnikova; H D Ochs; J Randolph-Habecker; S F Ziegler; R Storb; B Storer; D K Madtes; R Glenny; M S Mulligan Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: Benjamin M Horner; Kelly K Ferguson; Mark A Randolph; Joel A Spencer; Alicia L Carlson; Erica L Hirsh; Charles P Lin; Peter E M Butler Journal: J Plast Reconstr Aesthet Surg Date: 2009-03-26 Impact factor: 2.740